Navigating new frontiers: Ways to find space in the future RA market
In partnership with pharmaphorum
Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be the case for much longer, as several other candidates reach late-stage development.
Analysis of Therapy Watch data, a real-time syndicated market tracking tool and Living With data, our syndicated patient report series shows that JAK inhibitors have already made a strong impression in the European RA market, where their convenient oral administration advantage may override cost considerations that would otherwise favour biosimilar uptake.
This webcast, held in partnership with pharmaphorum uses the latest intelligence from both physicians and patients to look at emerging trends in the RA market, how these will shape the RA market of tomorrow and how companies can best position themselves for future success.
Topics covered in the webcast include:
- The European RA market
- Current status and market situation of JAK inhibitors (key EU5 countries)
- Uptake curve of JAKS compared to other new entrants and biosimilars
- The patient profile and unmet needs in RA
- Profile of physicians prescribing JAKS
- Country differences
- The future of new classes of JAK inhibitors
Sign up to receive Rapport
Rapport is our e-newsletter and online resource for sharing our expertise and experience in global healthcare market research. Sign up here »